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BAY 41-2272 activates host defence against local and  
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In our previous study, we have found that 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3
-yl]-pyrimidin-4-ylamine (BAY 41-2272), a guanylate cyclase agonist, activates human monocytes and the THP-1 
cell line to produce the superoxide anion, increasing in vitro microbicidal activity, suggesting that this drug can be 
used to modulate immune functioning in primary immunodeficiency patients. In the present work, we investigated 
the potential of the in vivo administration of BAY 41-2272 for the treatment of Candida albicans and Staphylococ-
cus aureus infections introduced via intraperitoneal and subcutaneous inoculation. We found that intraperitoneal 
treatment with BAY 41-2272 markedly increased macrophage-dependent cell influx to the peritoneum in addition to 
macrophage functions, such as spreading, zymosan particle phagocytosis and nitric oxide and phorbol myristate 
acetate-stimulated hydrogen peroxide production. Treatment with BAY 41-2272 was highly effective in reducing 
the death rate due to intraperitoneal inoculation of C. albicans, but not S. aureus. However, we found that in vitro 
stimulation of peritoneal macrophages with BAY 41-2272 markedly increased microbicidal activities against both 
pathogens. Our results show that the prevention of death by the treatment of C. albicans-infected mice with BAY 41-
2272 might occur primarily by the modulation of the host immune response through macrophage activation.
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Primary immunodeficiencies (PIDs) are a current 
topic of research, but the true incidence and prevalence 
of this group of diseases remains unknown. These dis-
eases are associated with high morbidity and mortality, 
sequelae, high economic and social costs, psychological 
stress and family breakdown inherent to chronic and se-
vere diseases (Modell et al. 2011). In recent years, signifi-
cant advancements in the understanding of the diagnosis 
and immunopathological mechanisms of PID have been 
achieved, but progress in PID therapy has been limited.
At a minimum, recurring infections, which represent 
the most common feature of PID, can be treated with low 
or moderate doses of appropriate antibiotics, which can 
help to prevent permanent damage to affected organs, 
thus promoting the long-term survival of patients while 
improving their quality of life (Fried & Bonilla 2009). 
When appropriate, immunoglobulin therapy is an accept-
ed treatment for some PID cases (Hoernes et al. 2011). 
Advanced treatments, such as those using interleukins, 
pegademase bovine and gamma interferon, can help in 
some complex cases (Errante et al. 2008, Booth & Gas-
par 2009, Roy-Ghanta & Orange 2010). Bone marrow 
(BM) transplantation and gene therapy may be appropri-
ate therapies for specific types of PID (Aiuti & Roncarolo 
2009, Chiesa & Veys 2012). However, even with these 
treatments, the development of alternative therapies is 
necessary that aim to boost the immune system.
In recent years, our group has focused on drugs with 
the potential to modulate, activate or retrieve immune cell 
function. Our previous results using 5-cyclopropyl-2-[1-
(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-py-
rimidin-4-ylamine (BAY 41-2272) which is an agonist of 
soluble guanylate cyclase (sGC), were promising in terms 
of mononuclear phagocyte activation. BAY 41-2272 en-
hances classical phagocyte responses, such as nicotin-
amide adenine dinucleotide phosphate (NADPH) oxidase 
system function and reactive oxygen species (ROS) re-
lease and also has been shown to increase phagocytosis, 
microbicidal activity and cytokine production in periph-
eral blood monocytes and a THP-1 cell line (de Oliveira-
Júnior et al. 2007, Soeiro-Pereira et al. 2012).
In this study, we found that intraperitoneal treatment 
with BAY 41-2272 after infection remarkably reduced 
the death rate in mice. Further, this activity of BAY 41-
2272 was dependent on the pathogen type, showing ef-
fectiveness against Candida albicans, but not Staphylo-
coccus aureus. We also found that BAY 41-2272 induced 
an inflammatory response in the abdomen of mice (i.e., 
the accumulation of macrophages), promoted ROS pro-
duction and enhanced antibacterial and antifungal in 
vitro activities. Our results suggest that BAY 41-2272 
prevents the death of infected mice through the activa-
tion of host innate immunity, confirming its potential as 
an anti-infective drug.
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MATERIALS AND METHODS
Chemicals - BAY 41-2272 was provided by Pharma 
Research Centre, Bayer AG (Germany). Instant-Prov was 
obtained from NewProv Ltd (Brazil). Phorbol-myristate-
acetate (PMA), transcutol (di-ethylene glycol ethyl ether), 
Cremophor-EL, thioglycollate, concanavalin A (Con A), 
carrageenan, zymosan A (Saccharomyces cerevisiae), 
crystal violet, horseradish peroxidase (HRP) type II, phe-
nol red, (2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazo-
lium-5-carboxanilide (MTT), Triton X-100 and dimethyl 
sulfoxide (DMSO) were purchased from Sigma (USA).
Animals - C3H/HePas male mice, weighing 20-25 
g, were used [Animal Facility, University of São Paulo 
(USP)]. The animals were assigned to plastic cages (5 
mice per cage) and housed under a 12-h light-dark cycle 
with access to unlimited supplies of filtered water and 
chow for one day before the initiation of the experiments. 
The studies were approved by the Animal Ethical Com-
mittee of the Institute of Biomedical Sciences of the USP, 
Brazil, according to the Guide for the Care and Use of 
Laboratory Animals prepared by the Institute of Labora-
tory Animal Resources, National Research Council and 
published by the National Academy Press (revised 1996).
Animal treatments - For the in vivo experiments, 
BAY 41-2272 was diluted in a transcutol, Cremophor-
EL and water solution (10/20/70 ratio, vol/vol/vol) to a 
final concentration of 1 mg/mL, as previously described 
(Bischoff et al. 2003). The animals were then weighed 
and the drug doses were adjusted to 0.3, 1.0, 3.0 and 10.0 
mg/kg. For in vitro stimulation, BAY 41-2272 diluted in 
a 0.7% DMSO solution was used at concentrations of 1.0 
and 3.0 µM, according to Bischoff et al. (2003). Treat-
ment with BAY 41-2272 was administered intraperitone-
ally (IP) for 48 h. A negative control group was injected 
with a saline solution and a positive control group was 
treated with 4% thioglycolate (Sigma) or Con A (0.5 mg/
kg) (Sigma). An additional control group was treated 
with a dilution solution only.
The ex vivo experiments were performed using resi-
dent macrophages or macrophages obtained from mice 
treated with BAY 41-2272. Treatments with penicillin G 
(5 kU/kg) and tetracycline (1 mg/kg) or itraconazole (20 
mg/kg) were also administered in the infection assays. 
To evaluate hydrogen peroxide (H2O2) production, an 
additional in vitro treatment with PMA (30 nM) (Sigma) 
was performed. Other reagents, treatments and models 
are described in the following specific methodologies.
Peritoneal and lymph node (LN) cell harvesting and 
BM cell counting. Mice were sacrificed by carbon di-
oxide (CO2) asphyxia at 48 h after the above-described 
treatment. Peritoneal cells were aseptically collected 
by washing the peritoneal cavity with 5 mL of sterile 
ice-cold phosphate-buffered saline (PBS) devoid of cal-
cium and magnesium ions. Resident macrophages were 
obtained from untreated mice. For total cell determi-
nation, nine volumes of peritoneal cells were added to 
one volume of 0.05% crystal violet dissolved in 30% 
acetic acid and the cells were counted using a bright-
line haemocytometer (Sigma). Differential cell counts 
were determined by cytospin preparations stained with 
Instant-Prov (NewProv).
After peritoneal fluid collection, the LN , spleen and 
femur were obtained. The LN and spleen were processed 
in 1 or 5 mL of PBS, respectively. The femur was washed 
with 1 mL PBS to obtain BM cells. For the total cell de-
termination, nine volumes of peritoneal cells were added 
to one volume of 0.05% crystal violet dissolved in 30% 
acetic acid and the cells were counted using a bright-line 
haemocytometer (Sigma).
Footpad oedema induction - Animals were anaesthe-
tised and injected subcutaneously (SC) with carrageenan 
(300 μg/paw in saline) into the right paw. Differences in 
the sizes of the injected vs. un-injected paws were used 
as an indicator of inflammation (paw oedema) (Winter 
et al. 1962). The properties of BAY 41-2272 were as-
sessed by injecting various doses of this drug (0.01-1.0 
mg kg-1) IP at 48 h before the administration of carra-
geenan. Control mice were injected with same volume of 
a solvent (0.5 mL olive oil). Con A (100 mg kg-1) served 
as a positive control. Inflammation was assessed at 60-
min intervals during a 4-h period.
Spreading assay - A spreading assay was performed 
according to Rabinovitch et al. (1977). Peritoneal cell sus-
pensions containing 2 × 106 cells were centrifuged and 
suspended in 1 mL of 5 mM glucose in PBS. Fifty mi-
crolitres of cell suspension were layered on glass coverslips 
and incubated for 1 h at 37ºC. The coverslips were gently 
rinsed in PBS and the glass-adherent cells were fixed in 
2.5% glutaraldehyde and examined with a phase contrast 
microscope at a 400X magnification. Two hundred mac-
rophages were counted and scored as round or spread. An 
index of macrophage spreading (SI) was then calculated 
as follows: SI = number of spreading macrophages × 
100)/200, i.e., SI = % of spreading macrophages.
Zymosan phagocytosis assay - A phagocytosis as-
say was performed according to Pinello et al. (2006). 
Peritoneal cell suspensions containing 2 × 106 cells were 
centrifuged and suspended in 1 mL of RPMI medium. 
The cells were dispensed over round glass coverslips (20 
mm) in six-well flat-bottomed microtest plates (Costar, 
USA) and the cultures were incubated at 37ºC for 20 
min. After incubation, culture supernatants were aspi-
rated and the non-adherent cells were removed. Adher-
ent monolayers were rinsed with PBS. Subsequently, 1 
mL of RPMI-1640 medium (Sigma) containing 5% heat-
inactivated foetal bovine serum was added to the cul-
tures. The cultures were maintained at 37ºC for 1 h in 
the presence of 1 mg/L S. cerevisiae zymosan (Sigma). 
The cultures were then washed with cold PBS to remove 
non-internalised particles. The cells were then fixed with 
0.5% glutaraldehyde (Sigma). An average of 200 mac-
rophages were counted using phase contrast microscopy 
to determine the phagocytic percentage. The phagocyto-
sis index (PI) was calculated as follows: PI = the number 
of macrophages with phagocytic activity × 100)/200 ad-
herent cells counted, i.e., PI = % of macrophages with at 
least two phagocytised zymosan particles.
H2O2 release and nitric oxide (NO) production - H2O2 
release and NO production were determined in a single 
macrophage sample using a previously described meth-
od (Cruz et al. 2007). To evaluate H2O2 release, a HRP-
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dependent phenol red oxidation microassay was used 
(Pick & Mizel 1981). For this assay, 2.0 x 106 peritoneal 
cells were suspended in 1 mL of freshly prepared phenol 
red solution [ice-cold PBS containing 5.5 mM dextrose, 
0.56 mM phenol red (Sigma) and 8.5 U/mL HRP type II 
(Sigma)]. One hundred microlitres of the cell suspension 
were added to each well and incubated with or without 
PMA (30 nM) (Sigma) for 1 h at 37ºC in a 5% CO2 humid 
atmosphere. Plates were centrifuged once at 150 g for 
3 min and the supernatants were transferred to another 
plate. The reaction was stopped with 10 μL sodium hy-
droxide. Absorbance was measured at 620 nm with a mi-
croplate reader (MR 5000; Dynatech Laboratories Inc). 
The conversion of absorbance to μM of H2O2 was per-
formed by comparison with a standard curve obtained 
with known concentrations of H2O2 (5-40 μM) diluted in 
RMPI medium (Pick & Keisari 1980).
Thereafter, the plates containing the cells were 
washed three times with PBS and the remaining adher-
ent macrophages were cultured in 100 μL of RPMI-1640 
medium (supplemented with 10 mM HEPES, 11 mM 
sodium bicarbonate, 100 U/mL penicillin, 100 μg/mL 
streptomycin, 2 mM L-glutamine, 23 mM L-asparagine, 
1 mM folic acid, 0.1 mM pyruvic acid and 5% foetal 
calf serum) for 48 h at 37ºC in a 5% CO2 humid atmo-
sphere. After the incubation, 50 μL of supernatants were 
collected and incubated with an equal volume of Griess 
reagent (1% sulfanilamide/0.1% naphthalene diamine 
dihydrochloride/2.5% phosphoric acid) for 10 min at 
room temperature (RT) to quantify the accumulation of 
nitrite (Ding et al. 1988). Absorbance was determined at 
550 nm. The conversion of absorbance to μM of NO was 
performed by comparison to a standard curve obtained 
with known concentrations (5-60 μM) of sodium nitrite 
diluted in RPMI medium.
Resistance of mice to C. albicans and S. aureus in-
fections - To assess the resistance of the BAY 41-2272-
treated animals to C. albicans (ATCC 90028) and S. au-
reus (ATCC 25923), two models of infection were used 
as follows: (i) the inoculation of pathogens in the peri-
toneal cavity followed by survival rate evaluation and 
(ii) the inoculation of pathogens SC into the footpad of 
the animals. For the first model, the animals were inocu-
lated IP with 0.5 × 106 C. albicans blastospores or 5 × 
106 colony-forming units of S. aureus. Forty-eight hours 
from inoculation to the establishment of infection, the 
animals were also treated daily IP with BAY 41-2272 
(1 or 3 mg/kg) or itraconazole (20 mg/kg) or penicillin 
G (5 KU/kg) and tetracycline (1 mg/kg) for three days. 
The survival rate of the animals was evaluated for 20 
days from the first day of inoculation. We attempted to 
perform survival experiments in mice with less than 12 
days of infection, but the results were reliable only for 
those infected for 20 days. For the second model, the 
animals were inoculated SC with the same concentra-
tions of pathogens into the footpad of the left paw and 
the right paw served as the control. At 48 h from inocula-
tion to the establishment of infection, the animals were 
treated daily IP or intralesionally (inoculated paw) with 
BAY 41-2272 (1 or 3 mg/kg) or itraconazole (20 mg/kg) 
or penicillin G (5 KU/kg) and tetracycline (1 mg/eg) for 
three days. Paw thickness was then measured after seven 
days from inoculation to assess the development of the 
lesion or infection.
Ex vivo and in vitro peritoneal macrophage microbi-
cidal activity - To assess microbicidal activity, an MTT 
oxidation microassay was used after the incubation of 
the cells with bacteria or fungi. For this assay, two pro-
tocols were used to treat the peritoneal macrophages 
as follows: (i) the resident peritoneal cells were stimu-
lated outside of the untreated animals (in vitro) and (ii) 
the cells were harvested from the animals treated as 
described previously in this protocol (ex vivo). After 
preparation, 2.5 × 105 cells were suspended in 200 µL 
of RPMI-1640 (without supplements) and distributed in 
a 96-well plate. The pathogens were then added at a 10:1 
(pathogens:macrophages) ratio for S. aureus and a 2:1 
ratio for C. albicans. Co-cultures were incubated for 2 
h at 37ºC with 5% CO2. After incubation, the plate was 
centrifuged and the supernatants were collected and 
stored at -80ºC for the subsequent cytokine dosage as-
say. The cell pellets were washed twice with PBS to re-
move non-phagocytosed pathogens. After the washings, 
Triton X-100 (1.5%) was added for 10 min at RT to lyse 
the macrophages and release the pathogens. The cells 
were then washed twice with PBS to remove the Triton 
X-100, 100 µL of MTT (0.5 mg/mL) was added and they 
were incubated for another 2 h at RT away from light. 
After this incubation, 100 µL of DMSO was added and 
another 30-min incubation was performed to release for-
mazan precipitate into the supernatant. After incubation, 
the plates were centrifuged (300 g for 3 min) and the su-
pernatants were transferred to a new plate. Absorbance 
was determined at λ = 570 nm with a microplate reader 
(Dynatech Laboratories Inc). The conversion from ab-
sorbance to percentage of cell death was achieved with 
the following equation: 1 - (OD of sample - OD of 90% 
killing)/(OD of 0% killing - OD of 90% killing) × 100. 
This calculation was performed based on the concen-
trations of pathogens representing 100-10% of the total 
number of pathogens incubated with the cells.
Data analysis and statistical procedures - Statisti-
cal analyses were carried out using Prism 5.0 software 
(GraphPad). The data are expressed as the mean ± stan-
dard error of the means for the animals per group and 
were compared by one-way, two-way or repeated mea-
sures analysis of variance, followed by Bonferroni’s post-
test for multiple comparisons (Erceg-Hurn & Mirosevich 
2008). Survival curves were compared with the log-rank 
(Cox-Mantel) test (Klein & Moeschberger 2003).
RESULTS
Peritoneal cell influx and cell recruitment to lym-
phoid organs - The mice were treated (or not) with BAY 
41-2272 (0.3-10 mg/kg IP) for 48 h, after which the peri-
toneal cavity was harvested and the spleen, BM and 
LN were collected (Fig. 1A). The cellular distribution 
showed that treatment with BAY 41-2272 induced a sig-
nificant increase in the total number of cells in the peri-
toneum compared with the control group (Fig. 1B). This 
cell population was composed primarily of macrophages 
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Fig. 1A: the diagram of this experimental protocol. 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-pyrimidin-4-
ylamine (BAY 41-2272) increases cell influx into the peritoneal cavity cellularity, but not lymphoid organs and bone marrow (BM). C3H/HePas 
mice were treated intraperitoneally (IP) with thyoglycolate (4% in saline solution) or BAY 41-2272 (0.3, 1.0, 3.0, 10.0 mg/kg). At 48 h after 
treatment the animals were sacrificed to collect peritoneal cells for total (B) and differential [C: macrophages; D: polymorphonuclear (PMN)] 
cell counts and to collect the spleen (E), BM (F) and mesenteric lymph node (LN) (G). The organs were processed for determination of the total 
number of cells. The results are shown as the mean ± standard error of the means of number of cells from five experiments in triplicate. Asterisks 
mean p < 0.05 compared to non-stimulated group (NS). Con A: concanavalin A.
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Fig. 2A: the diagram of this experimental protocol. 5-cyclopropyl-2
-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-pyrimidin-
4-ylamine (BAY 41-2272) potentiates inflammatory activity in a 
carrageenan model of paw oedema. C3H/HePas mice were treated in-
traperitoneally (IP) with concanavalin A (Con A) (0.5 mg/kg) or BAY 
41-2272 (1.0 or 3.0 mg/kg). At 48 h after treatment, carrageenan (300 μg/
paw) was injected in left footpad paw for measurement of oedema (paw 
size in mm) formed 3 h after the injection (B). The results are shown as 
the percentage of increase in paw size from the five experiments in trip-
licate. Asterisks mean p < 0.05 compared to carrageenan group (without 
pre-treatment with BAY 41-2272). PBS: phosphate-buffered saline.
(Fig. 1C), but the percentage of polymorphonuclear leu-
kocytes (PMNs) was also elevated in the group treated 
with this drug (Fig. 1D). All vehicles used (transcutol, 
Cremophor-EL and water solution and DMSO) had no 
effect on this or the other assays performed in this study 
(data not shown).
There were no differences in the numbers of cells in 
the other lymphoid organs, such as the spleen, BM or 
mesenteric LN s, in the animals treated with BAY 41-
2272 compared with the untreated animals (Fig. 1E-G). 
There was a trend of an increase in cell numbers only in 
the mesenteric LN s, indicating the recruitment of cells 
to this draining organ.
Carrageenan-induced footpad oedema - To evaluate 
the effect of BAY 41-2272 on the inflammatory process 
we used a carrageenan-induced mouse paw oedema 
model. Mice were treated (or not) with BAY 41-2272 
(0.3-10 mg/kg, IP) for 48 h, after which carrageenan 
(300 μg/paw) was injected into the footpad to measure 
oedema formation every hour for 4 h (Fig. 2A). Intrap-
eritoneal pre-treatment with BAY 41-2272 significantly 
increased paw oedema, which was observed at 180 and 
240 min after carrageenan injection (Fig. 2B). Similar 
data were observed for Con A. These results confirm the 
pro-inflammatory potential of BAY 41-2272.
Ex vivo macrophage activation induced by BAY 41-
2272 - spreading and phagocytosis - With regard to the 
pro-inflammatory activity generated by BAY 41-2272, 
spreading and phagocytosis were assessed as markers of 
peritoneal macrophage activation. The peritoneal cavity of 
mice that were treated (or not) with BAY 41-2272 (0.3-10 
mg/kg IP) for 48 h was harvested and peritoneal cells were 
incubated on glass slides to measure spreading or were in-
cubated with zymosan to evaluate phagocytosis (Fig. 3A). 
The macrophages obtained from the BAY 41-2272-treated 
mice showed an increase in spreading compared with the 
untreated animals (Fig. 3B), which is consistent with their 
increased phagocytic activities (Fig. 3C).
NO and H2O2 production - Mice were treated (or not) 
with BAY 41-2272 (0.3-10 mg/kg IP) for 48 h, after which 
the peritoneal cavity was harvested and peritoneal cells 
were incubated for 1 h with or without PMA (30 nM) to 
evaluate H2O2 release or were incubated for 48 h to eval-
uate NO production (Fig. 4A). It is known that phagocy-
tosis and ROS release are related and are responsible for 
many antimicrobial responses. However, in this study, 
despite an increase in phagocytic activity, we did not ob-
serve alterations in spontaneous H2O2 release (Fig. 4C). 
However, the addition of PMA to the macrophage cul-
tures from the BAY 41-2272-treated mice significantly 
increased the level of this metabolite (Fig. 4C).
Although pre-treatment did not induce the spontane-
ous release of H2O2, BAY 41-2272 significantly increased 
the spontaneous production of NO compared with the 
macrophages from the control group (Fig. 4B).
BAY 41-2272 increases survival of mice infected with 
fungi - The increases in phagocytosis and microbicidal 
activity suggest that BAY 41-2272 has potential for the 
treatment for infections. Therefore, C3H/HePas mice 
were challenged with C. albicans and S. aureus and the 
survival rates of these animals were evaluated. Mice 
were inoculated with C. albicans or S. aureus IP and 
after 48 h, they were treated (or not) with either BAY 
41-2272 (0.3-10 mg/kg IP) or itraconazole (20 mg/kg), 
penicillin G (5 KU/kg) and tetracycline (1 mg/kg) for 
three days. The survival rates of the animals were evalu-
ated for 20 days (Fig. 5A).
The results showed that intraperitoneal treatment 
with BAY 41-2272 at 48 h after infection significantly 
increased the survival rate of the C. albicans-infected 
mice (Fig. 5B), but had no effects on that of the S. aureus-
infected mice (Fig. 5C). In addition, as expected, itracon-
azole was completely effective in controlling Candida 
infection, maintaining the mouse survival rate at 100%.
BAY 41-2272 increases mouse response against local 
C. albicans, but not S. aureus infection - According to 
the observation that BAY 41-2272 increased the survival 
rate of C. albicans-infected mice, a model of infection 
in the animal footpad paw with the same pathogens was 
used (Fig. 6A). This protocol allowed for the evaluation 
of the direct effects of BAY 41-2272 on the site of infec-
tion (intralesional drug injection) and systemically (in-
traperitoneal drug administration).
Intralesional injection of BAY 41-2272 significantly 
reduced footpad swelling as induced by C. albicans, 
whereas the intraperitoneal treatment had no significant 
effect (Fig. 6B, C). The footpad swelling produced by S. 
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Fig. 3A: the diagram of this experimental protocol. 5-cyclopropyl-2-
[1-(2-f luoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-pyrimidin-
4-ylamine (BAY 41-2272) increases ex vivo peritoneal macrophage 
spreading and phagocytic activity of zymosan. C3H/HePas mice were 
treated intraperitoneally (IP) with concanavalin A (Con A) (0.5 mg/kg) 
or BAY 41-2272 (0.1, 1.0, 3.0, 10.0 mg/kg). At 48 h after treatment, the 
animals were sacrificed and peritoneal cells (2 × 106/mL) were harvest-
ed and incubated for 1 h at 37ºC on glass slides to define the percentage 
of spreading (B) or co-incubated with zymosan particles to set the per-
centage of phagocytosis (C) using phase contrast microscopy (400X). 
The results are shown as the mean ± standard error of the means of 
spreading or phagocytosis index from five experiments in triplicate. 
Asterisks mean p < 0.05 compared to non-stimulated group (NS).
Fig. 4A: the diagram of this experimental protocol. 5-cyclopropyl-2-
[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-pyrimidin-4-
ylamine (BAY 41-2272) increases ex vivo phorbol-myristate-acetate 
(PMA)-induced hydrogen peroxide (H2O2) release and nitric oxide (NO) 
production. C3H/HePas mice were treated intraperitoneally (IP) with 
concanavalin A (Con A) (0.5 mg/kg) or BAY 41-2272 (1.0, 3.0 mg/kg). 
At 48 h after treatment the animals were sacrificed and peritoneal cells 
(2 × 106/mL) were harvested and treated or not with PMA (30 nM) for 
evaluation of H2O2 production (C) by phenol red oxidation assay. Cells 
obtained from the peritoneum (2 × 106/mL) were also evaluated for NO 
production (B) by Griess reagent colorimetric assay. The results are 
shown as the mean ± standard error of the means of H2O2 or NO concen-
tration from five experiments in triplicate. *: p < 0.05 compared to non-
stimulated group (NS); #: p < 0.05 compared to NS treated with PMA.
aureus was not significantly altered by the subcutaneous 
or intraperitoneal BAY 41-2272 treatment (Fig. 6D, E).
BAY 41-2272 increases in vitro and ex vivo microbi-
cidal activities against C. albicans and S. aureus - For 
the in vivo models of infection, BAY 41-2272 generated 
a better response to C. albicans than to S. aureus. Thus, 
the effect of the in vitro or ex vivo treatment of perito-
neal macrophages with BAY 41-2272 was investigated 
by assessing its microbicidal activity in relation to both 
of these pathogens. Mice were treated (or not) with BAY 
41-2272 (0.3-10 mg/kg IP) for 48 h, after which the peri-
toneal cavity was harvested and peritoneal cells were 
incubated with C. albicans or S. aureus for 2 h to assess 
microbicidal activity (Fig. 7A).
Our results confirmed the effectiveness of the BAY 
41-2272 treatment, both in vitro and ex vivo, for increas-
ing the microbicidal activity of peritoneal macrophages 
(Fig. 7). This treatment increased both fungal (Fig. 7B, 
C) and bacterial (Fig. 7D, E) killing in a similar way 
and almost as effectively as Con A (positive control). 
These results demonstrate the potential of BAY 41-2272 
for treating fungal infections, specifically C. albicans, 
as shown by the in vivo model. Furthermore, these re-
sults showed that this treatment was effective in priming 
macrophages to respond against S. aureus.
DISCUSSION
The present study demonstrated that in vivo treat-
ment with BAY 41-2272 increased the host response 
against C. albicans. Moreover, BAY 41-2272 markedly 
increased macrophage functions, such as increased peri-
toneal influx, enhanced oxidative burst and NO release 
and increased zymosan phagocytosis and microbicidal 
activity against C. albicans and S. aureus. We also dem-
onstrated that BAY 41-2272 treatment increased the 
survival of mice with C. albicans peritoneal infection. 
Our findings support the hypothesis that BAY 41-2272 
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Fig. 5A: the diagram of this experimental protocol. Intraperitoneal 
treatment with 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]
pyridine-3-yl]-pyrimidin-4-lamine (BAY 41-2272) increases mice 
survival with Candida albicans infection (B), but not Staphylococcus 
aureus infection (C). C3H/HePas mice were inoculated intraperito-
neally (IP), with C. albicans (0.5 × 106 blastopores) or S. aureus (5 × 
106 colony-forming units). After 48 h, animals were treated or not with 
itraconazole (20 mg/kg) or penicillin G (5 kU/kg) and tetracycline (1 
mg/kg) or BAY 41-2272 (1.0 or 3.0 mg/kg) for 72 h. The animals were 
followed for 20 days from the day of inoculation to assess survival rate. 
Results represent a survival curve of 20 animals per group and four 
experiments in triplicate. Asterisks mean p < 0.05 compared to non-
stimulated group (NS).
activates the mononuclear phagocyte response and rep-
resents a potential application in the control of infections 
in immunocompromised hosts.
BAY 41-2272, especially after 48 h of administration, 
induced a significant increase in the total number of peri-
toneal cells, which primarily included macrophages. No 
significant increase in PMN number was observed, even 
during the first hours of treatment, indicating an atypical 
inflammatory reaction. There were no differences in cell 
number in other lymphoid organs, such as the spleen, BM 
and mesenteric LN s, in the animals treated with BAY 
41-2272. These data suggest an on-site drug effect, pri-
marily occurring through the activation of macrophages.
To clarify the extent of the activity of BAY 41-2272, 
we established a classical model of inflammation in-
duced by carrageenan (Reiter et al. 1985). Our data re-
vealed a pro-oedematous activity of BAY 41-2272 in a 
nonspecific inflammatory process. This pro-inflamma-
tory effect is possibly enhanced by the involvement of 
3,5-cyclic guanosine monophosphate (cGMP) in calcium 
flux (the control of actin and myosin fibres) and smooth 
muscle relaxation, leading to vasodilation and increased 
oedema (Schmidt et al. 2008, Morbidelli et al. 2010). It is 
important to note that carrageenan-induced paw oedema 
is largely dependent on PMN influx to the inflammatory 
site. Because the number of PMNs was unaltered by the 
BAY 41-2272 treatment, the increase in NO production 
can explain the carrageenan-induced oedema and NO 
has been previously described as a determinant of this 
response (Salvemini et al. 1996).
Along with evidence of inflammation generated by 
BAY 41-2272, we focused on the possibility of in vivo 
treatment with this compound to increase the immune 
response against pathogens. Therefore, we evaluated the 
function of peritoneal macrophages, which showed a sig-
nificant increase in the potential for spreading and phago-
cytic activity. This increase in spreading is important for 
migration to inflammatory sites and also for phagocytosis 
(Tatefuji et al. 1996). Signal pathways activated by BAY 
41-2272 are involved in cGMP generation and are associ-
ated with morphological changes required for migration, 
phagocytosis and spreading (VanUffelen et al. 1998, Borán 
& García 2007). The increase in BAY 41-2272-induced 
phagocytosis can be explained by protein kinase G acti-
vation, as has been recently shown by Bóran et al. (2008), 
promoting the rapid release and expansion of filaments in 
microglia cells and an increase in phagocytosis follow-
ing treatment with ANP (particulate GC stimulator) and 
dibutyryl-cGMP (permeable analogue of cGMP).
It is known that phagocytosis and ROS release oc-
cur in almost all antimicrobial responses (Flannagan et 
al. 2009). However, despite the increase in phagocytic 
activity, we did not observe an increase in spontaneous 
H2O2 release. This result may be related to anti-oxidant 
mechanisms activated by cGMP and especially by 
cAMP, such as the activation of peroxisome proliferator-
activated receptor-γ coactivator and glutathione peroxi-
dase 1 (Lu et al. 2010).
However, this strong effect on the NADPH oxidase sys-
tem appears to be temporary because the addition of PMA 
to macrophage cultures from treated mice induced the 
production of high levels of H2O2. This finding shows that 
treatment with BAY 41-2272 acts in priming macrophag-
es, which can subsequently enhance the responses of these 
cells to the presence of a pathogen. Furthermore, the fact 
that BAY 41-2272 also generated a “reversible antioxidant 
response” increases its therapeutic potential because this 
response promotes the elimination and inhibition of ex-
cess free radicals, protecting the organism against tissue 
damage during infection (Gupta et al. 2004).
Despite the fact that BAY 41-2272 treatment did not 
induce the spontaneous release of H2O2, it induced the 
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Fig. 6A: the diagram of this experimental protocol. Intraperitoneal and intralesional treatment with 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-
pyrazolo[3,4-b]pyridine-3-yl]-pyrimidin-4-ylamine (BAY 41-2272) increases host protection against Candida albicans, but not by Staphylococcus 
aureus infection. C3H/HePas mice were subcutaneously inoculated in the footpad paw with C. albicans (0.5 × 106 blastospores) (B, C) or S. aureus 
(5 x 106 colony-forming units) (D, E). After 48 h, animals were untreated or treated (same paw infected) with itraconazole (20 mg/kg) or penicillin 
G (5 kU/kg) or BAY 41-2272 (1.0 or 3.0 mg/kg). Treatments were done intraperitoneally (IP) or subcutaneous (SC) (intralesional) routes. After seven 
days of the inoculum, paw thickness (mm) was measured. The results are shown as the mean ± standard error of the means of paw size from five 
experiments in triplicate. Asterisks mean p < 0.05 compared to respective infected, but not treated control. The dashed line represents the paws 
average thickness of animals treated with saline. NS: non-stimulated group.
spontaneous production of NO. These results were ex-
pected because cGMP production involves an increase 
in the production of NO by calcium release (Proctor & 
Carpenter 2007). In other words, BAY 41-2272 provides 
signals to pre-activated macrophages (inducible NO syn-
thase expression) and initiates NO production. In bovine 
aortic endothelial cells, YC-1 (the BAY 41-2272 precur-
sor molecule) has been shown to release NO (Wohlfart et 
al. 1999). In vascular smooth muscle, BAY 41-2272 has 
also been reported to release endogenous NO (Teixeira 
et al. 2006). Other groups have already shown the strong 
synergism of BAY 41-2272 and NO, which stabilise the 
nitrosyl-haem complex to stimulate sGC activity and pro-
duce potent vasodilatory and antiplatelet effects (Stasch 
et al. 2001, Evgenov et al. 2006, Schmidt et al. 2008).
Because the BAY 41-2227 treatment significantly en-
hanced phagocytosis and NO production and primed cells 
for oxidative burst, we assessed its effects in peritoneal 
infection models. BAY 41-2272 significantly increased 
animal survival against C. albicans infection. However, 
this increase in survival was not observed with S. aureus 
infection. One possibility is that drug activity in vivo 
activates factors involved in the response to fungi, but 
not to Gram-positive bacteria. Another hypothesis is that 
treatment with BAY 41-2272 could increase the sensitiv-
ity of phagocytes to bacterial strategies of evasion.
Notably, the lowest dose of BAY 41-2272 (1 mg/kg) 
was more effective and the higher dose (3 mg/kg) was 
ineffective and it even caused a decrease in the animal 
survival rate. These data led us to consider that the pres-
ence of S. aureus drives the activation of resident cells, 
initiating an inflammatory process (Niska et al. 2012) 
that leads to an over-response, generating a condition 
similar to sepsis or septic shock. These acute inflam-
mation states are, in many cases, more harmful to the 
body than the infection itself (Nguyen & Nguyen 2009), 
leading to the death of the organism.
Using a less aggressive infection model (bacterial or 
fungal inoculation into the footpad), our results showed 
that the animals treated with BAY 41-2272, similar to 
the model of peritoneal cavity infection, showed a bet-
ter response to C. albicans, particularly when it was 
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Fig. 7A: the diagram of this experimental protocol. In vitro and ex vivo treatment with 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]
pyridine-3-yl]-pyrimidin-4-ylamine (BAY 41-2272) increases peritoneal macrophages microbicidal activity. C3H/HePas resident macrophages 
were harvested from mice and treated in vitro with BAY 41-2272 (1 µM or 3 µM) or concanavalin A (Con A) (2 mg/mL). Macrophages from animals 
treated for 48 h via the intraperitoneal route (Con A, 0.5 mg/kg or BAY 41-2272 1.0 or 3.0 mg/kg) were also obtained. These cells (2 × 106) were 
incubated with Candida albicans (2:1) (B, D) or Staphylococcus aureus (10:1) (C, E) for 2 h. The microbicidal activity was assessed by (2-methoxy-
4-nitro-5-sulphophenyl)-2H-tetrazolium-5-carboxanilide (MTT) reduction assay by bacteria recovered from macrophages. The results are shown as 
the mean ± standard error of the means of killing index from five experiments in triplicate. Asterisks mean p < 0.05 compared to respective infected, 
but not treated control. NS: non-stimulated group; PBS: phosphate-buffered saline. 
injected into the lesion. Because macrophages and neu-
trophils are considered to be the main cells involved 
in host defence against infections by Candida species 
(D’ostiani et al. 2000), we can again observe the action 
of the drug on phagocytes. Additional studies focusing 
on the involvement of Toll-like receptors, dectin receptor 
1 and Fc receptors are required to further understand the 
mechanisms of macrophage activation by BAY 41-2272 
in animals with Candida infections.
Regarding the response to S. aureus, we observed 
that the size of the paw was not changed by the BAY 41-
2272 treatment regardless of whether the treatment was 
intralesional (SC) or systemic (IP). Because our study 
provided strong evidence that BAY 41-2272 activates 
phagocytes, we again suggest that this compound might 
potentiate inflammation at the site of infection. Kins-
man et al. (1981) have assessed the inflammatory reac-
tions of protein A, which is a constituent of the S. aureus 
cell wall and identified its ability to increase tissue oe-
dema. This type of reaction caused by the aggregation of 
bacteria due to pro-inflammatory and pro-chemotactic 
responses facilitated by BAY 41-2272 can maintain the 
inflammatory cell influx to the site of response even af-
ter the removal of the pathogen.
In the in vivo models of infection, BAY 41-2272 was 
more effective in responding to the fungi compared to 
the bacteria. Thus, we investigated the in vitro and ex 
vivo microbicidal activities of peritoneal macrophages 
against the same pathogens. Our results showed that the 
in vitro treatment enhanced the microbicidal activities of 
the peritoneal macrophages against C. albicans and S. 
aureus and these increases were even more significant ex 
vivo. These results confirm the potential of BAY 41-2272 
for treating fungal infections, specifically C. albicans. 
We also show that this treatment is effective in promoting 
S. aureus killing. These data support our hypothesis that 
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the apparent non-resolution of S. aureus infection in vivo 
involves the maintenance of inflammation generated by 
the pathogen and potentiated by BAY 41-2272.
This increase in microbicidal activity is probably re-
lated to the oxidative burst, reactive nitrogen production 
and phagocytosis. However, we cannot exclude the pos-
sible involvement of other processes, such as phagosome 
pH acidification and lysosomal/granular enzyme release 
(Sokolovska et al. 2012), in addition to the participation 
of other cells. Importantly, the extensiveness of the ex 
vivo response indicates the relevance of chemical media-
tors and cells present in the physiological environment to 
the activation and modulation of phagocyte responses. 
It is likely that the action of BAY 41-2272 on other im-
mune cells creates an environment with significantly 
more stimuli for macrophage activation. These data, 
considering a complex physiological system, provide 
new evidence in support of the notion that BAY 41-2272, 
or its pathway (sGC-cGMP), can be used as a treatment 
for some infections, especially in immunocompromised 
patients. It is important to emphasise that the cardiovas-
cular effects of BAY 41-2272 (Thorsen et al. 2010, Joshi 
et al. 2011) did not limit its in vivo application.
We conclude that BAY 41-2272 causes a pro-inflam-
matory effect, activating mononuclear phagocytes (peri-
toneal macrophages). Moreover, treatment with BAY 
41-2272 significantly increases mouse responses to C. 
albicans (in vivo and in vitro) and S. aureus (in vitro), 
improving peritoneal macrophage microbicidal activi-
ties against these pathogens. Our group is actively inves-
tigating the pharmacological aspects of BAY 41-2272, 
aiming to clarify its signalling pathways and elucidate its 
effects on mononuclear phagocytes. With this informa-
tion, we intend to develop novel treatments to increase 
the quality of life of patients susceptible to infections, 
especially those with PID.
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